Background {#Sec1}
==========

Sepsis is a highly complex, life-threatening systemic disease caused by infection and has a high mortality rate. The number of sepsis patients is estimated to be around 27 million per year globally, of whom approximately 8 million people die, and the number of sepsis patients is increasing \[[@CR1]\]. The disease is sometimes referred to as *the most common but least recognized disease* \[[@CR2]\]. In the most severe form of sepsis, called septic shock, underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality \[[@CR3]\] and the effects of inflammation produced by the immune system spread systemically and induce an acute systemic disorder \[[@CR4]\]. Patients with septic shock must be treated urgently in an intensive care unit. Because of its complexity, the progression of septic shock varies from patient to patient, depending on age, sex, physical characteristics, physiological activity, underlying disease, and other factors. Therefore, treatment is largely based on doctors' skill obtained through practical experience, as is usually the case in the treatment of other diseases. Although several standard guidelines are available \[[@CR5], [@CR6]\], more effective, versatile, and reliable therapeutic strategies for emergency medicine are currently being sought.

The art of medicine, which emphasizes the individuality of patients, must be supported by a solid scientific understanding of disease based on human physiology. The art and science of medicine should be integrated in clinical practice at a much higher level than at present.

In the physical sciences and engineering, most of the knowledge accumulated to date about devices, components, and systems has been represented by models, most of which are presented quantitatively (mathematically). These models are available in various forms, such as scientific papers, patents, and software packages, and are used extensively as a concise representation of accumulated scientific knowledge in the research and development of new devices, components, and systems.

Accurate models of disease based on physiology and pharmacology could contribute to improving the treatment of diseases. Doctors could use such models to estimate the physiological state of their patients, predict the disease progression, and decide on treatment strategies, including the administration of drugs. Models could therefore provide a unified scientific background to clinical practice. Rami et al. extensively discussed and presented persuasive reasoning along these lines based on a historical review of treatment for sepsis \[[@CR7]\]. They aimed to demonstrate the potential of disease models in therapy and open the door to model-based therapy.

One problem with models is to incorporate the individuality of patients. We anticipate that individual differences can be accommodated by choosing model parameters carefully based on the patients' age, weight, sex, physiological status, underlying diseases, and other factors. Modern hospitals are well equipped with advanced diagnostic systems that would allow the easy customization of a disease model for each patient. In addition, mathematical models could help to promote a deeper understanding of diseases and establish a hypothesis of pathogenesis, improving our understanding of treatment methods.

Due to the complexity of disease physiology, it is difficult to model human diseases, and most mathematical models of disease physiology have so far focused on experimental animals, except models of diabetes and Parkinson's disease. Treatment strategies have been developed for diabetes based on mathematical models \[[@CR8]\]. The model developed by Kovatchev et al. \[[@CR9]\] was approved by the US Federal Drug Administration as an alternative to animal research for the approval of diabetes medications. Recently, we have constructed a diabetes model that includes brain-centered glucose metabolism and suggested an alternative therapeutic strategy for diabetes \[[@CR10]\]. A mathematical model based on brain metabolism has been constructed for Parkinson's disease and is recognized as a useful tool for investigating its pathogenesis \[[@CR11], [@CR12]\]. The importance of mathematical models in understanding the basic physiology in the progression of sepsis has been highlighted in previous work \[[@CR13]\]. In addition, Kendrick et al. published a clear description of the immune response to sepsis \[[@CR14]\], and Shi et al. discussed a bifurcation analysis of sepsis based on an immune system model \[[@CR15]\].

In this study, we aimed to construct a new mathematical model of septic shock based on clinical data. Among the diverse symptoms of sepsis patients, we focused on the damage caused to the cardiovascular system because septic shock most frequently damages the cardiovascular system. Our model combines the cardiovascular system, immune system, and pharmacological models, and we used existing models of these systems as our guiding tools \[[@CR16], [@CR17]\]. We focused on how inflammation resulting from immune activity affected the cardiovascular system and caused septic shock. Among the many possible effects of inflammation on the cardiovascular system, we selected increased vessel permeability, vasodilation, and reduced stroke volume \[[@CR18], [@CR19]\]. We incorporated these three factors into the combined model of the cardiovascular and immune systems, making the resulting model highly nonlinear. Through simulations, we showed that these three factors are sufficient to reproduce septic shock.

To complete the sepsis model, the nervous system and pharmacological responses to drug administration must be incorporated because they are crucial to the disease model. We could not measure the activity of the nervous system, but we incorporated qualitative physiological and empirical data to achieve a quantitative description in our model to reflect realistic physiological effects. The activity of the nervous system is weaker in patients with sepsis than in healthy people; thus, we introduced fatigue as a parameter of the sympathetic nervous system \[[@CR20], [@CR21]\]. In addition, the effects of drugs are reduced in sepsis patients compared with healthy people. Therefore, we used experimental data showing the reduced effects of an antihypertensive medicine in sepsis patients.

Method {#Sec2}
======

We constructed a mathematical model that represents the physiological dynamics of septic shock after infection and comprises cardiovascular system, immune system, nervous system, and pharmacological submodels. An overview of our model is shown in Fig. [1](#Fig1){ref-type="fig"}. There are various cardiovascular, nervous, and immune system models for different uses in the literature. Most of these models are closed in the single-target domain, although they must be connected to represent the disease. In this study, we focused on integrating these models, based on choosing appropriate existing models for the sepsis model. We used the cardiovascular system model proposed by Ursino and Innocenti \[[@CR17]\], which is comprehensive and includes the solute kinetics of each constituent in blood, as well as the sympathetic nervous system. Because the increase in vascular permeability is an important effect of inflammation on the cardiovascular system, the solute kinetics of the systemic capillaries in the model are essential in our sepsis model.Fig. 1Overview of the sepsis model

The immune system is complex, and quantitative models are still incomplete \[[@CR22], [@CR23]\]. We based our sepsis model on the model reported by Reynolds et al. \[[@CR16]\] because it is simple but captures the essential features of the immune system that are relevant to our sepsis model. We incorporated the effect of antibiotics into this model, following the proposal of Kitamura \[[@CR24]\].

The core of our sepsis model is in the link between the cardiovascular and immune systems. In other words, we model how inflammatory responses damage the cardiovascular system. As stated in the Background section, we considered the three effects of inflammation on the cardiovascular system---increased vessel permeability, vasodilation, and reduced stroke volume---all of which contribute to reducing blood pressure. To quantify these effects, we represented the three parameters as functions of inflammation. Because inflammation manifests in diverse ways, it is hard to represent as a simple physical quantity; it is more an abstract and collective quantity. In contrast, permeability, vasodilation, and stroke volume are tangible physical parameters with clear units of measurement. The model connected these physical parameters with an abstract representation of the severity of inflammation. This was an unavoidable difficulty and an intriguing aspect of sepsis modeling.

Next, we briefly describe each model.

The cardiovascular system model is composed of five compartments, namely, the pulmonary atrium (*pa*), right atrium (*ra*)*,* left atrium (*la*), systemic arteries (*sa*), and the systemic veins (*sv*) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Cardiovascular system model

Each compartment is described by its volume *V*, pressure *P*, incoming flow rate *q*~*in*~, outgoing flow rate *q*~*out*~, and compliance *C* representing the compartment capacity, subject to the conservation of mass$$\documentclass[12pt]{minimal}
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The right cardiac output *q*~*r*~ and left cardiac output *q*~*l*~ are represented by.$$\documentclass[12pt]{minimal}
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The solute kinetics of the capillary system that transports the blood components to the tissues are important in our model. We focus on the material exchange between vessels and the interstitial fluid. The total blood volume *V* is subject to the following transport law:$$\documentclass[12pt]{minimal}
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Total blood volume *V* consists of six components, namely,$$\documentclass[12pt]{minimal}
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The baroreflex is governed by the sympathetic nervous system, which elevates the blood pressure when the baroreceptors detect a decrease in blood pressure. The increase in blood pressure is achieved via elevation of the heart rate, increased vascular resistance, and increased venous blood volume unloading \[[@CR25]\].

Let *a* be the action of the sympathetic nervous system. The mechanisms of nervous system action are different for each component of the baroreflex; thus, *a* for heart rate elevation is denoted by *a*~*f*~, *a* for increasing vascular resistance is denoted by *a*~*r*~, and *a* for increasing unloaded blood volume is denoted by *a*~*υ*~. The elevation in heart rate mediated by sympathetic action is described as$$\documentclass[12pt]{minimal}
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According to Poiseuille's law, vessel resistance *R* is inversely proportional to the fourth power of the vessel radius *r*, that is,$$\documentclass[12pt]{minimal}
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If *a*~*r*~ increases above *a*~0*r*~, then *K*~*r*,\ *cr*~ and resistance *R* decrease.

Finally, the unloaded blood volume *V*~*u*~ in equation (7) is assumed to be reduced by the sympathetic nervous system in the same way as in equation ([10](#Equ10){ref-type=""}),$$\documentclass[12pt]{minimal}
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                \begin{document}$$ {V}_u={V}_{u0}{K}_{v, cr},\kern0.5em {K}_{V, cr}=\frac{1}{1-{a}_{0v}+{a}_v}=\frac{1}{A_V}, $$\end{document}$$where *V*~*u*0~ is the normal unloaded blood volume *V*~*u*~ given in equation (7) \[[@CR17]\]. The reduction of the unloaded volume implies an increase in circulating volume *V*~*f*~ due to equation ([5](#Equ5){ref-type=""}), assuming that total volume *V* is fixed.

Now we quantify the baroreflex and its fatigue. Let *X* be the average output of the baroreceptors that detect the right arterial blood pressure, *P*~*ra*~, and the systemic arterial blood pressure, *P*~*sa*~, which is assumed to be$$\documentclass[12pt]{minimal}
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The normal arterial blood pressure, *P*~*ra*0~, and systemic blood pressure, *P*~*sa*0~, depend on individual patients.

Since the nerve activities *a*~*f*~, *a*~*r*~ and *a*~*υ*~ have the same mathematical representations, we omit their subscripts f, r, and υ in the following description. We assume that *a* changes between its minimum, *a*~*min*~, and maximum, *a*~*max*~, due to a change in *X*. Thus, *a* is assumed to be represented by a sigmoid function of *∆X*:$$\documentclass[12pt]{minimal}
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The normal level of sympathetic nerve activity *a*~0~ corresponds to the activity level when *∆X* = 0. Hence, equation ([15](#Equ15){ref-type=""}) implies$$\documentclass[12pt]{minimal}
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If sympathetic nerve activity is sustained above its normal level for a long time, then the action gradually decreases due to fatigue (e.g., \[[@CR20]\]). To represent this effect, we introduce fatigue factor γ as$$\documentclass[12pt]{minimal}
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If *a*~0~ \< *a* for an extended time, γ increases and *a* is reduced according to equation ([18](#Equ18){ref-type=""}). Equations ([17](#Equ17){ref-type=""}) and ([16](#Equ16){ref-type=""}) are nonlinear differential equations.

Sepsis is caused by excessive inflammation triggered by the immune system after infection. The dynamics of the immune system play an important role in evaluating the progression of sepsis. However, because the immune system is complex, mathematical models of immune system dynamics are not well developed, although there have been several attempts to quantify the dynamics \[[@CR23], [@CR25]\]. We base our sepsis model on the model proposed by Reynolds et al. \[[@CR16]\] because their model is simple but captures some essential features of the immune system that are relevant to sepsis.

The dynamic model is composed of the four state variables, pathogen population *P*, inflammation *N*^∗^, damage *D*, and anti-inflammatory mediator *C*~*A*~ (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR16]\].Fig. 3Overview of the immune system model \[[@CR16]\]

The interactions among these variables are described as follows.

The dynamics of *P* are described by.$$\documentclass[12pt]{minimal}
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The first term represents the logistic growth of pathogen *P*, where *k*~*pg*~ is the growth rate and *P*~∞~ is the carrying capacity of *P*. The second term represents the non-specific local immune response toward *P* characterized by the Michaelis--Menten equation \[[16](#Equ16){ref-type=""}\]. The third term represents the removal of the pathogen by phagocytic immune cells, which is proportional to inflammation *N*^∗^, restricted by the anti-inflammatory mediator *C*~*A*~, as shown in equation ([20](#Equ20){ref-type=""}). The forth term represents the effect of antibiotic dosage proposed by Kitamura \[[@CR24]\]. Here, *C*~*f*~ denotes the free concentration of antibiotic, which is subject to the following dynamics.$$\documentclass[12pt]{minimal}
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Here, *X*~1~ denotes antibiotic dosage, *X*~2~ its blood concentration, *k*~*a*~ the absorption coefficient and *k*~*e*~ the degradation coefficient.

The inflammation dynamics are represented by$$\documentclass[12pt]{minimal}
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The first term of equation ([24](#Equ24){ref-type=""}) is a simplified representation of the initiation of inflammation caused by *P*, *D*, and *N*^∗^ represented by their linear combination in equation ([25](#Equ25){ref-type=""}), and *s*~*nr*~ and *μ*~*nr*~ are Michaelis--Menten parameters for the inflammatory reactions. Function *g* introduced in equation ([20](#Equ20){ref-type=""}), which represents the saturating factor due to the presence of anti-inflammatory mediator *C*~*A*~, is also used to represent the initiation of inflammation. The second term represents the degradation.

*C*~*A*~ is subject to the dynamics$$\documentclass[12pt]{minimal}
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Here, *S*~*c*~ denotes a source of *C*~*A*~ and the second term represents the production of *C*~*A*~ from damage *D* and inflammation *N*^∗^ by a Michaelis--Menten term with inhibition mediated by *C*~*A*~ itself. The third term represents the degradation. More detailed descriptions are found in Reynolds et al. \[[@CR16]\].

Damage *D* is an abstract quantity in the paper by Reynolds et al. \[[@CR16]\], but here we give it a physical meaning to represent cardiovascular system damage. There are several ways to identify cardiovascular damage, and we take reduced stroke volume *S*~*l*~, introduced in equation (3), because it affects the whole system substantially. We describe the damage as$$\documentclass[12pt]{minimal}
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Next, we quantify how inflammation lowers blood pressure. The most important factor is the increase in the permeability of the capillaries due to inflammation \[[@CR16], [@CR18]\]. In our model, capillary permeability is represented by coefficient *L*~*a*~ in equation ([5](#Equ5){ref-type=""}). We assume that the inflammation population *N*^∗^ increases *L*~*a*~ following a sigmoid function given by$$\documentclass[12pt]{minimal}
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The vessel radius *r* is given by equation (9), and we assume *A*~*r*~ in (10), which represents the dilation factor, *K*~*r*,\ *cr*~, is now reduced by *N*^∗^ as$$\documentclass[12pt]{minimal}
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Finally, we assume that inflammation damages the function of the heart substantially \[[@CR13], [@CR23]\]. We assume that inflammation decreases the left stroke volume *S*~*l*~ defined by equation (3) as$$\documentclass[12pt]{minimal}
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Lowered blood pressure in septic shock is treated by infusion and drugs. Infusion is represented by the term *Q*~*inf*~ in equation ([4](#Equ4){ref-type=""}). An infusion may contain many blood components and varies according to the condition of the patient. However, we omitted a detailed description of the components and assume the infusion to be 0.9% saline.

There are several drugs used to treat severe hypotension in sepsis patients, of which noradrenaline and dopamine are the most commonly used in clinical practice. Antibiotics are also used to dispose the pathogen and are represented by the fourth term of equation (19).

The dose-response curve of noradrenaline (*NA*~eff~) is normally represented by a sigmoid function$$\documentclass[12pt]{minimal}
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Noradrenaline acts in various ways to elevate blood pressure. Here, we simply assumed that noradrenaline increases the effect of sympathetic nerve activity *a*. Thus, after the dosage *NA*~*in*~, sympathetic nerve activity is assumed to be increased by a factor proportional to *NA*~*eff*~, that is,$$\documentclass[12pt]{minimal}
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Another major drug for sepsis therapy is dopamine, the main effects of which are increasing the heart rate and stroke volume \[[@CR26]\]. These effects are described as$$\documentclass[12pt]{minimal}
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Parameters {#Sec3}
----------

Our model contained a number of parameters that must be quantified to perform simulations. We classified them into three groups according to the time periods in which they were used (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Parameter classification

The parameters in group 1 are used throughout the whole simulation, even before infection. They represent the physical characteristics of the patient, such as weight, sex, and underlying diseases. All parameters in the cardiovascular system are taken from the paper by Ursino and Innocenti \[[@CR17]\]. Their numerical values are shown in Table A1 of the Appendix.

The parameters related to the nervous system used in equations (9)--(18) are shown in Table A2 in the Appendix. Some of them are taken from Ursino and Innocenti's paper \[[@CR17]\], and others are estimated mainly based on the literature. Some parameters are fitted based on MATLAB tools to minimize the gap between data and simulation. .

The initial value of the total blood volume *V* depends on sex and weight. We assume that the total blood volume is 8% of body weight for men and 7% for women \[[@CR29]\]. We also consider the possibility of heart failure as an underlying disease. The quantitative description of heart failure is presented in the Results section.

The parameters in group 2 are used after the initiation of infection and include the immune system parameters. We take these parameters from the paper by Reynolds et al. \[[@CR16]\] (Table A3). This group also contains parameters that represent the effects of infection on the cardiovascular system. The most important parameters in this group are those that represent the increase in blood permeability *L*~*a*~ denoted by equation ([5](#Equ5){ref-type=""}). There are several papers that report attempts to measure blood permeability. It was reported that the maximum value of *L*~*a*~ during infection is almost 6 times greater than normal *L*~*a*~ \[[@CR30]--[@CR32]\], and we used this observation in our model. The other parameters in equation ([29](#Equ29){ref-type=""}) are chosen by tuning and are listed in Table A4 in the Appendix.

The growth rate of the pathogen, given by parameter *k*~*pg*~, is used to represent the severity of the infection. Other parameters are taken from the model reported by Reynolds et al. \[[@CR16]\].

The parameters in group 3 are pharmacological parameters that represent drug efficacy \[[@CR24]\]. The dose-response curve of noradrenaline is represented by sigmoid function in equation ([32](#Equ32){ref-type=""}) and the numerical values of the associated parameters have been experimentally obtained for healthy subjects \[[@CR25]\]. The dose-response curve for sepsis patients may differ from that for healthy people. The numerical values of the parameters in equation ([30](#Equ30){ref-type=""}) are listed in Table A5.

Results {#Sec4}
=======

We validated the model in two steps. In the first step, we established *a standard patient model* capturing some essential features of sepsis progression and treatment effect, at least qualitatively. For this purpose, the relationship between the severity of the infection and the difficulty of recovery was important in the disease model. We represented the severity of infection through the value of parameter *k*~*pg*~ in equation (19), which describes the growth rate of the pathogen.

We took heart failure as a representative example of an underlying disease in patients due to the strong link between sepsis and cardiac insufficiency \[[@CR33], [@CR34]\]. A typical consequence of heart failure is a reduction in stroke volume. According to the European Society of Cardiology guidelines published in 2016 \[[@CR34]\], heart failure is defined as a circulatory condition in which the ejection fraction (EF) is below 40%, where EF is defined as the ratio of the left heart cardiac stroke volume to the left heart blood volume. Normal EF is between 50 and 60%. We noticed that if the left cardiac stroke volume *S*~*l*~ in equation (3) was reduced by 22%, we obtained a 40% drop in EF, which is consistent with the definition of heart failure with reduced EF. Therefore, we used this reduction in *S*~*l*~ to represent heart failure as the underlying disease.

We classified the severity of infection as mild, moderate, and severe, based on the range of parameter *k*~*pg*~. Sepsis progression was represented in the time courses of mean arterial pressure (MAP) and heart rate. The recovery can be judged when the time course of MAP and heart rate returned to the normal or original level.

For mild infection, where *k*~*pg*~ is small (*k*~*pg*~ = 0.2), the disease spontaneously resolves without treatment (black curve). The internal immune system works effectively, although the blood pressure decreases slightly and temporarily (Fig. [7(a)](#Fig7){ref-type="fig"}). Thus, natural healing due to the innate immune system is achieved. An additional simulation shows that saline infusion (red curve) and noradrenaline (green curve) improve the recovery process in the mild infection case (Fig. [7(a)](#Fig7){ref-type="fig"}).Fig. 7(**a**) Patient with a mild infection (*k*~*pg*~ = 0.2). (**b**) Patient with a moderate infection (*k*~*pg*~ = 0.45). (**c**) Patient with a severe infection (*k*~*pg*~ = 1.50). Time courses of sepsis development

For moderate infection (*k*~*pg*~ = 0.45), the internal immune system alone cannot control the effect of inflammation and the blood pressure continues to decrease (Fig. [7(b)](#Fig7){ref-type="fig"}). However, infusion can prevent the decrease in blood pressure. Blood pressure does not decrease even after the infusion rate is reduced to the minimum level after 1 h of intensive infusion, which is consistent with clinical data.

For severe infection with a high *k*~*pg*~ (*k*~*pg*~ = 1.50), infusion alone is not enough to raise the blood pressure and noradrenaline is needed (Fig. [7(c)](#Fig7){ref-type="fig"}).

We conducted the same simulations for a case with heart failure as an underlying disease. In this patient, no spontaneous healing occurred. Even in the case of mild infection, the blood pressure continued to drop without treatment, as shown in Fig. [8(a)](#Fig8){ref-type="fig"} (black curve). This is consistent with clinical observations that heart failure often seriously affects sepsis progression. An infusion can resolve the drop in0020blood pressure, as in patients without heart failure. The time courses in Figs. [7(b)](#Fig7){ref-type="fig"}(c) and 8(b)(c) are similar, indicating that in cases of moderate and severe infection, the sepsis damage dominates the effect of heart failure as an underlying disease, which is also consistent with some clinical observations.Fig. 8(**a**) Mild infection with heart failure. (**b**) Moderate infection with heart failure. (**c**) Severe infection with heart failure. Time courses of sepsis development in patients with heart failure

The two in silico experiments show that our model reproduced the progression of septic shock and the outcome of the treatment, at least qualitatively.

Now, we validated our model quantitatively using real clinical data from three patients with septic shock who were treated in Tokyo Women's Medical University Hospital. Basic information about the patients is given in Table [1](#Tab1){ref-type="table"}.Table 1Basic Information about PatientsPatient's DataTreatmentSexAgeWeight\[kg\]Underlying\
DiseaseInfusionNADOAAntibioticsPatient1male5166Heart failure\*○○×○Patient2female9945Alzheimer○×○×Patient3male7965Diabetes\
Atrial fibrillation○○××\*assumed

For model validation, we used blood pressure and heart rate time courses, which were fundamental state variables for tracking disease progression and therapy. In Figs. [9](#Fig9){ref-type="fig"}, [10](#Fig10){ref-type="fig"}, [11](#Fig11){ref-type="fig"}, the time courses of blood pressure and heart rate records are shown with the infusion and drug administration records of each patient. The time according to the records is shown on the horizontal axis. The severity of infection was set as moderate for all cases.Fig. 9Clinical data for patient 1Fig. 10Clinical data for patient 2Fig. 11Clinical data for patient 3

We observed marked different time courses of sepsis progression among the three patients. We must adjust the parameters of the model to reproduce the data for each patient. We performed simulations to check whether the model parameters could be adjusted to fit the computational results to the clinical data. Parameters were adjusted starting with the model constructed for a *standard patient* in the first step of validation. Figure [12](#Fig12){ref-type="fig"} compares the simulation results and clinical data for patient 1. The blood pressure (MAP) and heart rate computed by our model fit the clinical data well.Fig. 12Comparison of the simulation results and clinical data for patient 1

A sudden drop in blood pressure occurred 17 h after treatment began, which the model did not reproduce.

Normally, a drop in blood pressure is associated with an elevated heart rate according to the baroreflex response. However, in this case, the patient's heart rate also dropped. Because this patient was a heavy habitual alcohol drinker (ca. 150 g/day), we thought a heart dysfunction was induced during septic shock. Thus, we imposed external noise *f*~*noise*~ on heart rate *f* given in equation (3) as$$\documentclass[12pt]{minimal}
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*f*~*noise*~ is shown in Fig. [13](#Fig13){ref-type="fig"}. We also assumed that a sudden reduction of arterial baroreceptor gain *q*~*r*~ in equation (3) occurred. The simulation results incorporating these events are shown in Fig. [13](#Fig13){ref-type="fig"}. The results reproduce the sudden drop in heart rate and the effect on blood pressure, as well as the recovery process (Fig. [14](#Fig14){ref-type="fig"}). Usually, disease progression is affected by many unexpected factors that cannot be represented in a model. However, a model can explain unexpected events when reasonable assumptions are made. In this case, our simulation was validated due to the close link between cardiac dysfunction and sepsis \[[@CR35]\].Fig. 13Simulation results after *f*~*noise*~ was introducedFig. 14Comparison of the simulated and clinical data after *f*~*noise*~ was introduced

Figure [15](#Fig15){ref-type="fig"} compares the simulation results and clinical data for patient 2.Fig. 15Comparison of the simulation results and clinical data for patient 2

This patient was stable with low blood pressure and high heart rate when given infusion therapy. The administration of dopamine contributed to the elevation of the heart rate, which was reproduced in the simulation.

Figure [16](#Fig16){ref-type="fig"} compares the simulation results and clinical data for patient 3.Fig. 16Comparison of the simulation results and clinical data for patient 3

The gradual recovery of the blood pressure and the associated normalization of the heart rate due to infusion and noradrenaline administration are closely reproduced by the simulation.

The parameter tuning for fitting data was done by updating several parameters of the basic model used in the first step of the qualitative validation. Table [2](#Tab2){ref-type="table"} lists the parameters changed for accommodating the individual patients. Among 12 parameters, five are related to the vessel resistance. Remarkably, only a handful of parameters need to be adjusted for accommodating differences among patients, and also the differences among the parameter values are not large.Table 2Patients parameter informationParameterStandard PatientPatient1Patient2Patient3Normal value of heart rate *f*(*f*~0~)1.2beat/s1.2beat/s1.25beat/s0.9beat/sNormal value of arteriovascular radius *r*(*r*~0~)3.0*μ*m3.0*μ*m2.85*μ*m2.9*μ*mInitial total blood Volume(*V*~0~)3150ml5300ml3150ml5200mlSeverity(*k*~*pg*~)-0.55 /h0.7 /h0.6 /hRate of vessel radiusr dilation(*k*~*EX*~)40503544Compliance of sa(*C*~*sa*~)4ml/mmHg4ml/mmHg2.8ml/mmHg2.8ml/mmHgResistance of the systemic circulation upstream of arteriolar capillaries(*R*~*s*2~)0.2247mmHg*∙* s/ml0.2247mmHg*∙* s/ml0.2247mmHg*∙* s/ml0.2472mmHg*∙* s/mlResistance of the systemic circulation downstream of arteriolar capillaries(*R*~*s*3~)0.1124mmHg*∙* s/ml0.1124mmHg*∙* s/ml0.1124mmHg*∙* s/ml0.1236mmHg*∙* s/mlResistance of sv(*R*~*sv*~)0.011mmHg*∙* s/ml0.011mmHg*∙* s/ml0.011mmHg*∙* s/ml0.012mmHg*∙* s/mlResistance of pa(*R*~*pa*~)0.1124mmHg*∙* s/ml0.1124mmHg*∙* s/ml0.1124mmHg*∙* s/ml0.1236mmHg*∙* s/mlResistance of pv(*R*~*pv*~)0.0056mmHg*∙* s/ml0.0056mmHg*∙* s/ml0.0056mmHg*∙* s/ml0.0062mmHg*∙* s/mlRate at which activated phagocytes(*N\**) consume pathogen(*k*~*pn*~)1.8 /*N\**-units/h1.8 /*N\**-units/h1.8 /*N\**-units/h1.26/*N\**-units/h\*The table indicates the differences of the parameters among the three patients. The confidence intervals of the parameters are omitted in the table

An important parameter that is not listed in Table [2](#Tab2){ref-type="table"} is the time interval between the time of infection and the start of treatment. At the start of the simulation, the initial value of pathogen P is set to be positive. This implies that the starting time of the simulation is the time of infection. We must decide when treatment is started (when the initial data was obtained) based on the goodness of fit between data and simulations. This tuning is one-dimensional and was not difficult. It conveys, however, valuable information about when the patient was infected before hospitalization.

Discussion {#Sec5}
==========

The first part of the simulation showed that our model captures the fundamental dynamics of sepsis progression and the effects of therapy. The severity of infection could be represented by the growth rate *k*~*pg*~ of the pathogen in the immune model in equation (19). We considered mild, moderate, and severe infections, and treatment with nothing, saline infusion, and saline infusion plus medicine to identify the level of difficulty of recovery. The results are shown in Fig. [7](#Fig7){ref-type="fig"} and summarized in Table [3](#Tab3){ref-type="table"}.Table 3Severity and intensity of treatmentMildModerateSevereNo treatment○××Infusion○○×Infusion and medicine○○○○: recovered ×: not recovered

The results show that the severity of the infection matched the intensity of treatment required for recovery.

Many sepsis patients have underlying diseases; thus, we used heart failure as an example of an underlying disease that can be modeled by changing some parameters. We showed that the patient with heart failure does not recover from even a mild infection without treatment, which is consistent with clinical experience. These simulations show that our model captures the essential features of sepsis and that the interactions quantified in our model among the immune, cardiovascular, and nervous system submodels are justified, at least qualitatively.

In the second part of the simulation, we validated our model to fit clinical data of three sepsis patients (Figs. [9](#Fig9){ref-type="fig"}--[11](#Fig11){ref-type="fig"}). As stated in the Background section, the progression of sepsis differs among patients, and the symptoms are also different. Although it is necessary to customize the models for each patient by choosing appropriate model parameters, there are a large number of parameters making customization appear difficult. However, as was shown in Table [3](#Tab3){ref-type="table"}, the number of parameters tuned for fitting was not very many and most parameters were unchanged from the general model of a standard patient used for the first part of simulations (Figs. [7](#Fig7){ref-type="fig"} and [8](#Fig8){ref-type="fig"}). The most obvious differences were body weight and sex, which affect the total blood volume. Age differences were taken into account by choosing the vessel flexibility and radius, and the strength of the sympathetic nerve activity was tuned slightly to accommodate the data. They are natural, easy, and reasonable customizations for individuality.

Heart failure is included as an underlying disease in patient 1. The sudden drop in blood pressure is accommodated by a sudden drop in heart rate, which is usually a symptom of heart failure. This suggests the possibility that the model can explain sudden events occuring during the course of treatment. For patient 3, we ignored diabetes as an underlying disease, but still obtained a good fit between the model and data.

The most finely balanced and important parameter for fitting the model to real data is the time of infection or the starting time of the simulation. Typically, a patient has already been infected when admitted to the hospital and does not know when they were infected. As discussed in the Method sections, we could estimate the time of infection through a one-dimensional search. Estimating the time of infection with the model by finding the most appropriate initial time of simulation gives valuable information for determining the treatment strategy for a patient. This is an important benefit of disease modeling.

Because sepsis is a serious disease that affects almost all parts of the body, it may lead to other subsequent diseases, which we have not incorporated in the model. However, even when an unexpected physical event occurred, the model could identify the cause. Patient 1 had a sudden drop in blood pressure during treatment (Fig. [12](#Fig12){ref-type="fig"}), which was explained by a heart attack (Fig. [14](#Fig14){ref-type="fig"}). Although this was an estimate, it could provide valuable information for medical staff.

Conclusion {#Sec6}
==========

We have constructed a simple mathematical model of septic shock to represent and predict disease progression and the effects of treatments. The model combined the cardiovascular and immune systems through the effects of inflammation, which are represented by increases in vessel permeability, vasodilation, and stroke volume reduction. We assumed the following three effects of sympathetic nerve activity responding to severe hypotension caused by infection: elevated heart rate, increase in vessel resistance, and decrease in blood volume unloading. We also introduced the fatigue effect of the sympathetic nervous system. The weaker effects of drugs in sepsis patients were also considered.

We demonstrate that our model is a reasonable model of septic shock and represents the therapeutic effects of treatment through in silico experiments. We also show the reduced therapeutic effects in patients with sepsis who have underlying heart failure.

We validated our model based on the clinical data of three sepsis patients and showed that the model reproduced the treatment course. Moreover, the model reproduced sudden physiological events in patients.

Although our model represents specific aspects of septic shock, which is complex and involves almost every organ in diverse ways, we show that we can construct a model that captures the essential features of this disease. We discuss the potential of the model to help with clinical decision making and promoting a deeper understanding of sepsis.

Because the model contained a number of parameters that must be set for simulations, the difficulty in determining appropriate numerical values has been identified as one of the main barriers to using mathematical models in medicine. The customization of models for individual patients is an additional difficulty. However, we found that a standard patient model can be constructed based on the existing physiological, medical, and pharmacological knowledge, as described in the first part of the Results section, although some parameters had to be taken from experimental data on animals. We were able to customize the standard patient model for three patients based on their age, sex, weight, and underlying disease, by tuning only several parameters of the standard patient model. The simulations well reproduced the data.

Our results suggest that disease modeling could help medical staff predict the patient's condition and establish a clinical strategy for recovery. The possibility of estimating the infection time before treatments start is another benefit of the disease model.

The disease model extracts knowledge about human physiology relevant to the target disease, and the model can be customized by selecting relatively small number of parameters. We consider that the general and individual data are accommodated well in the model and that their integration can bring great benefits to clinical practice. We hope that our model will play a role in guiding practitioners toward model-based therapies. To achieve this goal, our model must be more reliable and versatile, and must be validated using a larger amount of clinical data, which we intend to tackle in the next step of our research.

Appendix {#Sec7}
========

Table 4Cardio vascular system model (Ursino model) parametersParameterValueDescriptionSource*C* ~*sa*~4ml/mmHgCompliance of sa\[[@CR16]\]*C* ~*sv*~111.11ml/mmHgCompliance of sv\[[@CR16]\]*C* ~*ra*~31.25ml/mmHgCompliance of ra\[[@CR16]\]*C* ~*pa*~6.56ml/mmHgCompliance of pa\[[@CR16]\]*C* ~*pv*~25.37ml/mmHgCompliance of pv\[[@CR16]\]*C* ~*la*~19.23ml/mmmHgCompliance of la\[[@CR16]\]*R* ~*s2*~0.2247mmHg∙ s/mlHydraulic resistance of the systemic circulation upstream of arteriolar capillaries\[[@CR16]\]*R* ~*s3*~0.1124mmHg∙ s/mlHydraulic resistance of the systemic circulation downstream of arteriolar capillaries\[[@CR16]\]*R* ~*sv*~0.011mmHg∙ s/mlHydraulic resistance of sv\[[@CR16]\]*R* ~*pa*~0.1124mmHg∙ s/mlHydraulic resistance of pa\[[@CR16]\]*R* ~*pv*~0.0056mmHg∙ s/mlHydraulic resistance of pv\[[@CR16]\]*L* ~*a*~0.01ml/mmHg/sPermeability coefficient of arterial capillaries\[[@CR16]\]*L* ~*v*~0.062ml/mmHg/sPermeability coefficient of venular capillaries\[[@CR16]\]*V* ~*usa*~611.3mlUnstressed volume of sa\[[@CR16]\]*V* ~*ura*~25mlUnstressed volume of ra\[[@CR16]\]*V* ~*upa*~124mlUnstressed volume of pa\[[@CR16]\]*V* ~*upv*~120mlUnstressed volume of pv\[[@CR16]\]*V* ~*ula*~25mlUnstressed volume of la\[[@CR16]\]*k* ~*l*~20ml/mmHgSlope of the stroke volume versus the atrial pressure relationship for the left heart\[[@CR16]\]*k* ~*r*~34.028ml/mmHgSlope of the stroke volume versus the atrial pressure relationship for the right heart\[[@CR16]\]*p* ~*la0*~2.8mmHgx -axis intercept of the stroke volume versus atrial pressure relationship for the left heart\[[@CR16]\]*p* ~*ra0*~1.82mmHgx -axis intercept of the stroke volume versus atrial pressure relationship for the right heart\[[@CR16]\]*V* ~*n*~5300mlTotal blood volume in the basal condition\[[@CR16]\]*V* ~*rc*~1300mlRed blood cell volume\[[@CR16]\]*p* ~*san*~100mmHgIntravascular pressure in the sa in the basal condition\[[@CR16]\]*p* ~*svn*~5mmHgIntravascular pressure in the sv in the basal condition\[[@CR16]\]*p* ~*ran*~4mmHgIntravascular pressure in the ra in the basal condition\[[@CR16]\]*p* ~*pan*~17mmHgIntravascular pressure in the pa in the basal condition\[[@CR16]\]*p* ~*pvn*~7mmHgIntravascular pressure in the pv in the basal condition\[[@CR16]\]*p* ~*lan*~6.5mmHgIntravascular pressure in the la in the basal condition\[[@CR16]\]*k* ~*Na*~25ml/sMass transfer coefficient of the cellular membrane for sodium\[[@CR16]\]*β* ~*Na*~0.0704Mass transfer coefficient of the cellular membrane for sodium\[[@CR16]\]*k* ~*K*~6.67 ∙ 10^−2^ml/sMass transfer coefficient of the cellular membrane for potassium\[[@CR16]\]*β* ~*K*~28.2Mass transfer coefficient of the cellular membrane for potassium\[[@CR16]\]*k* ~*U*~13ml/sMass transfer coefficient of the cellular membrane for urea\[[@CR16]\]*β* ~*U*~1Mass transfer coefficient of the cellular membrane for urea\[[@CR16]\]*k* ~*f*~4 ∙ 10^−3^*L*^2^/s/mmolWater exchange coefficient of the cellular membrane\[[@CR16]\]*M* ~*eq,ic*~150mmolAmount of other osmotically efficient solutes in the intracellular compartment\[[@CR16]\]*M* ~*eq,ex*~150mmolAmount of other osmotically efficient solutes in the extracellular compartment\[[@CR16]\]*E* ~*is*~24.5mmHg/LInterstitial space elastance\[[@CR16]\]*V* ~*isn*~11LBasal volume of the interstitial fluid\[[@CR16]\]*V* ~*icn*~25LBasal volume of the intracellular fluid\[[@CR16]\]*c* ~*p,pin*~7.4g/dlBasal protein concentration in the plasma\[[@CR16]\]*c* ~*p,isn*~1.37g/dlBasal protein concentration in the interstitial fluid\[[@CR16]\]*M*~*k,ic*~(0)3535mEqInitial amount of potassium in the intracellular fluid\[[@CR16]\]*Mk,ex*(0)75mEqInitial amount of potassium in the extracellular fluid\[[@CR16]\]*M*~*Na,ic*~(0)250mEqInitial amount of sodium in the intracellular fluid\[[@CR16]\]*M*~*Na,ex*~(0)2130mEqInitial amount of sodium in the intracellular fluid\[[@CR16]\]*M*~*U,ic*~(0)2130mEqInitial amount of urea in the intracellular fluid\[[@CR16]\]*M*~*U,ex*~(0)375mmolInitial amount of urea in the extracellular fluid\[[@CR16]\]*Q* ~*F*~0.2083ml/sUltrafiltration rate of the replacement fluid\[[@CR16]\]*Q* ~*inf*~0ml/sUltrafiltration rate of the replacement fluid\[[@CR16]\]*c* ~*Na,d*~142mEq/LUltrafiltration rate of the replacement fluid\[[@CR16]\]*c* ~*Kd*~62mEq/LUltrafiltration rate of the replacement fluid\[[@CR16]\]*c* ~*Ud*~0Concentration of urea in the dialysate\[[@CR16]\]*F* ~*p*~0.94Plasma fractions\[[@CR16]\]*F* ~*R*~0.72Red blood cell water fractions\[[@CR16]\]*γ* ~*U*~1Fraction of red blood cell water that participates in the transfer through the dialyzer\[[@CR16]\]*R* ~*DU*~1Donnan ratio for urea in red cells\[[@CR16]\]*γ* ~*Na*~0Fraction of red blood cell water that participates in the transfer through the dialyzer\[[@CR16]\]*γ* ~*K*~0Fraction of red blood cell water that participates in the transfer through the dialyzer\[[@CR16]\]*Q* ~*B*~3ml/sBulk blood flow through the dialyzer\[[@CR16]\]*D* ~*Na*~2.67ml/sDialysance (or clearance) of sodium\[[@CR16]\]*D* ~*K*~2.67ml/sDialysance (or clearance) of potassium\[[@CR16]\]*D* ~*U*~2.67ml/sDialysance (or clearance) of urea\[[@CR16]\]*σ* ~*Rn*~0.7303mmHg∙ s/mlBasal value of the sigmodideal static characteristic for the mechanism of systemic resistance control\[[@CR16]\]Δ~*σR*~1.4mmHg∙ s/mlAmplitude of the sigmodideal static characteristic for the mechanism of systemic resistance control\[[@CR16]\]*τ* ~*R*~6sTime constant of the mechanism of systemic resistance control\[[@CR16]\]*G* ~*aR*~0.02/mmHgCentral gain of the arterial controls for the mechanism of systemic resistance control\[[@CR16]\]*G* ~*cR*~0.7/mmHgCentral gain of the cardiopulmonary controls for the mechanism of systemic resistance control\[[@CR16]\]*σ* ~*V\ n*~2900mlBasal value of the sigmodideal static characteristic for the mechanism of venous unstressed volume control\[[@CR16]\]Δ~*σV*~500mlAmplitude of the sigmodideal static characteristic for the mechanism of venous unstressed volume control\[[@CR16]\]*τ* ~*V*~20sTime constant of the mechanism of venous unstressed volume control\[[@CR16]\]*G* ~*aV*~10.8/mmHgCentral gain of the arterial controls for the mechanism of venous unstressed volume control\[[@CR16]\]*G* ~*cV*~417/mmHgCentral gain of the cardiopulmonary controls for the mechanism of venous unstressed volume control\[[@CR16]\]*σ* ~*Tn*~0.833sBasal value of the sigmodideal static characteristic for the mechanism of heart period control\[[@CR16]\]Δ~*σT*~0.75sAmplitude of the sigmodideal static characteristic for the mechanism of heart period control\[[@CR16]\]*τ* ~*T*~2sTime constant of the mechanism of heart period control\[[@CR16]\]*G* ~*aT*~0.015/mmHgCentral gain of the arterial controls for the mechanism of heart period control\[[@CR16]\]*G* ~*cT*~0/mmHgCentral gain of the cardiopulmonary controls for the mechanism of heart period control\[[@CR16]\]*p* ~*lat*~4.5mmHgThreshold value of left atrial pressure for activation of the sympathoinhibitory mechanism\[[@CR16]\]*G* ~*σ*~4.5mmHgGain constant of the sympathoinhibitory mechanism\[[@CR16]\]*τ* ~*σ*~120sTime constant of the sympathoinhibitory mechanism\[[@CR16]\]*τ* ~*ϵ*~2700s(acetate dialysis only)Time constant of the acetate effect upon peripheral vessels\[[@CR16]\]

Table 5Nervous system model parametersParameterValueDescriptionSources*a*~*f*~,max1.3175Maximum value of sympathetic nerve activity *a*~*f*~Estimated*a*~*r*~,max8.6993Maximum value of sympathetic nerve activity *a*~*r*~Estimated*a*~*V*~,max0.9443Maximum value of sympathetic nerve activity *a*~*V*~Estimated*a*~*f*~,min0.1896Minimum value of sympathetic nerve activity *a*~*f*~Estimated*a*~*r*~,min2.6996Minimum value of sympathetic nerve activity *a*~*r*~Estimated*a*~*V*~,min0.8206Minimum value of sympathetic nerve activity *a*~*V*~Estimated*k* ~*γ*~3.0 × 10^−5^Sympathetic nerve effect coefficient for*γ*Estimated*a* ~*f*0~0.680Sympathetic nervous activity for *f*~0~Estimated*a* ~*r*0~0.549Sympathetic nervous activity for *r*~0~Estimated*a* ~*V*0~0.0935Sympathetic nervous activity for *V*~0~Estimated*f* ~0~1.2beat/sNormal value of heart rate *f*Estimated by \[[@CR16]\]*R* ~s1,0~0.0113mmHg·s/mlNormal value of arteriolar vascular resistance *R*~*s*1~Estimated by \[[@CR16]\]*V* ~*usv*,0~2.9 × 10^−3^mlNormal value of venous unstressed blood bolume *V*~*usv*~Estimated by \[[@CR16]\]*r* ~*0*~3.0*μ*mNormal value of arteriovascular radius *r*Estimated by \[[@CR17]\]*k* ~*f*~1.01Sympathetic nerve effect coefficient for *f*Estimated*k* ~*r*~8.2Sympathetic nerve effect coefficient for *r*Estimated*k* ~*V*~1.0Sympathetic nerve effect coefficient for *V*~*usv*~Estimated

Table 6Immune system model and antibiotics pharmacological effect model parametersParameterValueDescriptionSources*k* ~*pm*~0.6/M-units/hRate at which the non-specific local response(M) eliminates pathogen\[[@CR15]\]*k* ~*mp*~0.01/P-units/hRate at which the non-specific local response is exhauseted by pathogen\[[@CR15]\]*k* ~*pn*~1.8/*N*\*-units/hRate at which activated phagocytes(*N*\*) consume pathogen\[[@CR15]\]*p* ~*∞*~20·10^6^/ccMaximum pathogen population\[[@CR15]\]*s* ~*m*~0.005/M-units/hSource of non-specific local response\[[@CR15]\]*μ* ~*m*~0.002/hDecay rate for the non-specific local response\[[@CR15]\]*s* ~*nr*~0.08N~R~-units/hSource of resting phagocytes\[[@CR15]\]*μ* ~*nr*~0.12/hDecay rate of resting phagocytes\[[@CR15]\]*μ* ~*n*~0.05/hDecay rate of activated phagocytes\[[@CR15]\]*k* ~*dn*~0.35D-units/hMaximum rate of damage produced by activated phagocytes\[[@CR15]\]*μ* ~*d*~0.02/hDecay rate of damage\[[@CR15]\]*k* ~*cn*~0.04/*C*~*A*~-units/hMaximum production rate of the anti-inflammatory mediator\[[@CR15]\]*k* ~*cnd*~48*N*\*-units/D-unitsRelative effectiveness of activated phagocytes and damaged tissue in inducing production of the anti-inflammatory mediator\[[@CR15]\]*s* ~*c*~0.0125*C*~*A*~-units/hSource of the anti-inflammatory mediator\[[@CR15]\]*μ* ~*c*~0.1/hDecay rate of the anti-inflammatory meditor\[[@CR15]\]*k* ~*nn*~0.01/*N*\*-units/hActivation of resting phagocytes by previously activated phagocytes and their cytokines\[[@CR15]\]*k* ~*np*~0.1/P-units/hActivation of resting phagocytes(*N*~*R*~)by pathogen\[[@CR15]\]*k* ~*nd*~0.02/D-units/hActivation of resting phagocytes by damage(D)\[[@CR15]\]*c* ~*∞*~0.28*C*~*A*~-unitsControls the strength of the anti-inflammatory mediator(*C*~*A*~)\[[@CR15]\]*x* ~*dn*~0.06*N*\*-unitsDetermines level of activated phagocytes needed to bring damage production up to half its maximum\[[@CR15]\]*k*25Coefficient for *S*~*rate*~Estimated*k* ~0~18Coefficient for *S*~*d*~Estimated*k* ~*D*~0.35/hCoefficient of *S*~*d*~ for *D*Estimated*S* ~0~73.8mlNormal value of stroke volume *S*Estimated by\[[@CR32]\]*k* ~*a*~1/hAbsorption rate constant from the gut compartment to the central compartment\[[@CR23]\]*k* ~*e*~1/hElimination rate constant from the central compartment\[[@CR23]\]*f* ~*p*~1Free fraction in plasma\[[@CR23]\]*V* ~*d*~1l/kgDistribution volume\[[@CR23]\]*ε*0.01/hMaximum kill rate constant\[[@CR13]\]*γ*0.5Hill coefficient\[[@CR13]\]

Table 7Blood pressure reduction model parametersParameterValueDescriptionSources*L*~*a*~,min0.01ml/mmHg/sNormal vascular permeability\[[@CR16]\]*L*~*a*~,max0.06ml/mmHg/sMaximum vascular permeabilityEstimated by\[[@CR29]\]\[[@CR31]\]*EC* ~50,\ *La*~0.22Half maximal effective *N*\* valueEstimated*slope* ~*La*~1.0Maximum gradient value of *L*~*a*~Estimated*k* ~*EX*~50Rate of vessel radiusr dilationEstimated*EC* ~50,\ *EX*~0.5Half maximal effective EX valueEstimated*slope* ~*EX*~3.0Maximum gradient value of EXEstimated*k* ~*s*~1.0Effect of inflammatory to stroke volumeEstimated

Table 8Noradrenaline pharmacologival effect model parametersParameterValueDescriptionSource*N A*~*eff*~ ,max1.05Maximum effect of noradrenalineEstimated by \[[@CR36]\]*EC* ~50,\ *N\ A*~0.53kg/*μ*gHalf maximal effective NA valueEstimated by \[[@CR36]\]*slope* ~*N\ A*~1.09Maximum gradient value of NAEstimated*G* ~*N\ A,r*~5.0Interaction strength of noradrenaline to arteryEstimated by \[[@CR25]\]*G* ~*N\ A,V*~0.18Interaction strength of noradrenaline to veinEstimated by \[[@CR25]\]
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